Fenwick represented A-Alpha Bio, a synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, in its $22.4 million Series A2 financing. The round was led by previous investor Perceptive Xontogeny Ventures with participation from Madrona and other existing investors. Breakout Ventures joined the round as a new investor.
A-Alpha Bio intends to use the funds for further development of its AlphaSeq and AlphaBind platforms and accelerate their oncology-focused internal pipeline. More information can be obtained from the company’s announcement.
The transaction was led by corporate partner Bill Bromfield and associates Sam Millang and Warren Pugash.